{"title":"成人心脏病患者的代谢综合征及其相关因素:一项横断面比较小组研究。","authors":"Alemayehu Abera, Mekdes Shifeta, Sisay Tesfaye, Bedasa Addisu, Agete Tadewos Hirigo","doi":"10.1177/20480040241271789","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>There is limited information about the extent of metabolic syndrome (MetS) among subjects with cardiac diseases in Ethiopia. Therefore, this study aimed to determine the prevalence and associated factors of MetS among adults with cardiac diseases.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at Hawassa University Comprehensive Specialized Hospital in southern-Ethiopia between May 2021 and August 2021. Data pertaining to the study were collected from 319 participants (153 cardiac and 166 non-cardiac groups) using the WHO stepwise approach. The International Diabetes Federation (IDF) and the revised National Cholesterol Education Program: Adult Treatment Panel III (ATP) were used to define MetS.</p><p><strong>Results: </strong>The prevalence of MetS was 44.2% and 50.2% in IDF and ATP III, respectively. Among the cardiac group, 54.9% had MetS in IDF criteria, compared to 34.3% in the non-cardiac group (<i>p</i> < .001); whereas, it was 60.1% in the cardiac group and 41% in non-cardiac group (<i>p</i> < .001) by ATP III. Age >60 years, waist-height ratio ≥5, high waist-hip ratio, body mass index 25-29.9 and ≥30 kg/m<sup>2</sup> were significantly associated with higher odds of MetS in both IDF and ATP III. Also, smoking history and monthly income were associated with MetS by ATP III, while being female was associated with higher odds of MetS by IDF.</p><p><strong>Conclusion: </strong>More than half of the subjects with cardiac diseases developed MetS as compared to non-cardiac controls. Periodic screening and focusing on the identified modifiable high-risk factors such as body weight, smoking, and central adiposity is important to effectively mitigate the risk of further comorbidity and complications in this high-risk population.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"13 ","pages":"20480040241271789"},"PeriodicalIF":1.4000,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329911/pdf/","citationCount":"0","resultStr":"{\"title\":\"Metabolic syndrome and its associated factors among adults with cardiac diseases: A cross-sectional comparative group study.\",\"authors\":\"Alemayehu Abera, Mekdes Shifeta, Sisay Tesfaye, Bedasa Addisu, Agete Tadewos Hirigo\",\"doi\":\"10.1177/20480040241271789\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>There is limited information about the extent of metabolic syndrome (MetS) among subjects with cardiac diseases in Ethiopia. Therefore, this study aimed to determine the prevalence and associated factors of MetS among adults with cardiac diseases.</p><p><strong>Methods: </strong>A cross-sectional study was conducted at Hawassa University Comprehensive Specialized Hospital in southern-Ethiopia between May 2021 and August 2021. Data pertaining to the study were collected from 319 participants (153 cardiac and 166 non-cardiac groups) using the WHO stepwise approach. The International Diabetes Federation (IDF) and the revised National Cholesterol Education Program: Adult Treatment Panel III (ATP) were used to define MetS.</p><p><strong>Results: </strong>The prevalence of MetS was 44.2% and 50.2% in IDF and ATP III, respectively. Among the cardiac group, 54.9% had MetS in IDF criteria, compared to 34.3% in the non-cardiac group (<i>p</i> < .001); whereas, it was 60.1% in the cardiac group and 41% in non-cardiac group (<i>p</i> < .001) by ATP III. Age >60 years, waist-height ratio ≥5, high waist-hip ratio, body mass index 25-29.9 and ≥30 kg/m<sup>2</sup> were significantly associated with higher odds of MetS in both IDF and ATP III. Also, smoking history and monthly income were associated with MetS by ATP III, while being female was associated with higher odds of MetS by IDF.</p><p><strong>Conclusion: </strong>More than half of the subjects with cardiac diseases developed MetS as compared to non-cardiac controls. Periodic screening and focusing on the identified modifiable high-risk factors such as body weight, smoking, and central adiposity is important to effectively mitigate the risk of further comorbidity and complications in this high-risk population.</p>\",\"PeriodicalId\":30457,\"journal\":{\"name\":\"JRSM Cardiovascular Disease\",\"volume\":\"13 \",\"pages\":\"20480040241271789\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-08-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11329911/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JRSM Cardiovascular Disease\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20480040241271789\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JRSM Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20480040241271789","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
摘要
目的:有关埃塞俄比亚心脏病患者代谢综合征(MetS)程度的信息十分有限。因此,本研究旨在确定代谢综合征在成人心脏病患者中的患病率和相关因素:这项横断面研究于 2021 年 5 月至 2021 年 8 月期间在埃塞俄比亚南部的哈瓦萨大学综合专科医院进行。采用世卫组织逐步法收集了 319 名参与者(153 名心脏病患者和 166 名非心脏病患者)的相关数据。国际糖尿病联合会(IDF)和修订后的美国国家胆固醇教育计划(National Cholesterol Education Program:结果:结果:在 IDF 和 ATP III 中,MetS 患病率分别为 44.2% 和 50.2%。在 IDF 和 ATP III 的标准中,心脏病组中有 54.9% 的人患有 MetS,而非心脏病组中只有 34.3% 的人患有 MetS(P.P.60 岁、腰高比≥5、腰臀比高、体重指数 25-29.9 和≥30 kg/m2 与 MetS 的发生几率显著相关)。此外,在 ATP III 中,吸烟史和月收入与 MetS 相关,而在 IDF 中,女性与 MetS 的高几率相关:结论:与非心脏病对照组相比,半数以上的心脏病患者出现了 MetS。定期筛查并重点关注已确定的可改变的高危因素,如体重、吸烟和中心性肥胖,对于有效降低这类高危人群进一步合并症和并发症的风险非常重要。
Metabolic syndrome and its associated factors among adults with cardiac diseases: A cross-sectional comparative group study.
Objective: There is limited information about the extent of metabolic syndrome (MetS) among subjects with cardiac diseases in Ethiopia. Therefore, this study aimed to determine the prevalence and associated factors of MetS among adults with cardiac diseases.
Methods: A cross-sectional study was conducted at Hawassa University Comprehensive Specialized Hospital in southern-Ethiopia between May 2021 and August 2021. Data pertaining to the study were collected from 319 participants (153 cardiac and 166 non-cardiac groups) using the WHO stepwise approach. The International Diabetes Federation (IDF) and the revised National Cholesterol Education Program: Adult Treatment Panel III (ATP) were used to define MetS.
Results: The prevalence of MetS was 44.2% and 50.2% in IDF and ATP III, respectively. Among the cardiac group, 54.9% had MetS in IDF criteria, compared to 34.3% in the non-cardiac group (p < .001); whereas, it was 60.1% in the cardiac group and 41% in non-cardiac group (p < .001) by ATP III. Age >60 years, waist-height ratio ≥5, high waist-hip ratio, body mass index 25-29.9 and ≥30 kg/m2 were significantly associated with higher odds of MetS in both IDF and ATP III. Also, smoking history and monthly income were associated with MetS by ATP III, while being female was associated with higher odds of MetS by IDF.
Conclusion: More than half of the subjects with cardiac diseases developed MetS as compared to non-cardiac controls. Periodic screening and focusing on the identified modifiable high-risk factors such as body weight, smoking, and central adiposity is important to effectively mitigate the risk of further comorbidity and complications in this high-risk population.